3rd Quarter - Report — MAYO CLINIC for MAYO CLINIC (2019)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

MAYO CLINIC

Client

MAYO CLINIC

Income

—

Expenses

$225,000

Expense method

A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
3rd Quarter - Report (this page)	Jan 10, 2020	$225,000	Replaced
3rd Quarter - Amendment	Sep 23, 2020	$225,000	Replaced
3rd Quarter - Amendment	Oct 25, 2020	$225,000	Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

Opioid Epidemic (H.R. 6); clinical pain management

Lobbyist	Covered position, as disclosed
HALENA GAZELKA	—

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH)

Bills named: H.R. 6 (116th)

Medicare/Medicaid MMM

Medicare physician payments; Medicare hospital payments; Medicare clinical lab payments; Quality;

Lobbyist	Covered position, as disclosed
PIPER NIETERS SU	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH)

Medical/Disease Research/Clinical Labs MED

PAMA (Lab Payments); Medical Research Funding; Regulatory Relief; Laboratory Diagnostic Tests

Lobbyist	Covered position, as disclosed
KAREN SEALANDER	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE

Health Issues HCR

Telemedicine; Laboratory Medicine payment and oversight

Lobbyist	Covered position, as disclosed
PIPER NIETERS SU	—

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE; Centers For Medicare and Medicaid Services (CMS)

Science/Technology SCI

Telemedicine technology; New Diagnostic tests, Precision Medicine; NextGen Sequencing

Lobbyist	Covered position, as disclosed
PIPER NIETERS SU	—

Contacted: HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE

Pharmacy PHA

Drug Shortage; Drug Pricing; Opioid Epidemic (H.R. 6); 340B Program

Lobbyist	Covered position, as disclosed
PIPER NIETERS SU	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.